Research ExplorerJournalsCNS DRUGS Publications

CNS DRUGS

1 - 5 out of 5Page size: 50

Publications

  1. 2019

  2. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses

    Kohlschütter, A., Schulz, A., Bartsch, U. & Storch, S., 04.2019, In: CNS DRUGS. 33, 4, p. 315-325 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. 2017

  4. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise

    Westphal, M., Maire, C. L. & Lamszus, K., 09.2017, In: CNS DRUGS. 31, 9, p. 723-735 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. 2015

  6. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management

    Lüdecke, D., Schöttle, D., Karow, A., Lambert, M. & Naber, D., 01.01.2015, In: CNS DRUGS. 29, 1, p. 41-6 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. 2009

  8. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

    Naber, D. & Lambert, M., 2009, In: CNS DRUGS. 23, 8, p. 649-659 8.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. 2004

  10. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

    Lambert, M. & Naber, D., 2004, In: CNS DRUGS. 18, 2, p. 3-5 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review